SBHMY Quote, Financials, Valuation and Earnings

Hong Kong Pharma Digital Technology Holdings has a net margin of -- compared to Sino Biopharmaceutical's net margin of --. Sino Biopharmaceutical's return on equity of 8.57% beat Hong Kong Pharma Digital Technology Holdings's return on equity of --.

Sino Biopharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Hong Kong Pharma Digital Technology Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Sino Biopharmaceutical has higher upside potential than Hong Kong Pharma Digital Technology Holdings, analysts believe Sino Biopharmaceutical is more attractive than Hong Kong Pharma Digital Technology Holdings.

Sino Biopharmaceutical has a beta of 0.412, which suggesting that the stock is 58.775% less volatile than S&P 500. In comparison Hong Kong Pharma Digital Technology Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sino Biopharmaceutical has a quarterly dividend of $0.08 per share corresponding to a yield of 2.17%. Hong Kong Pharma Digital Technology Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sino Biopharmaceutical pays -- of its earnings as a dividend. Hong Kong Pharma Digital Technology Holdings pays out -- of its earnings as a dividend.

Sino Biopharmaceutical quarterly revenues are --, which are smaller than Hong Kong Pharma Digital Technology Holdings quarterly revenues of --. Sino Biopharmaceutical's net income of -- is lower than Hong Kong Pharma Digital Technology Holdings's net income of --. Notably, Sino Biopharmaceutical's price-to-earnings ratio is 17.83x while Hong Kong Pharma Digital Technology Holdings's PE ratio is 5.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical is 2.16x versus 0.52x for Hong Kong Pharma Digital Technology Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Prenetics Global has a net margin of -- compared to Sino Biopharmaceutical's net margin of -137.21%. Sino Biopharmaceutical's return on equity of 8.57% beat Prenetics Global's return on equity of -23.16%.

Sino Biopharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Prenetics Global has an analysts' consensus of $13.00 which suggests that it could grow by 160%. Given that Prenetics Global has higher upside potential than Sino Biopharmaceutical, analysts believe Prenetics Global is more attractive than Sino Biopharmaceutical.

Sino Biopharmaceutical has a beta of 0.412, which suggesting that the stock is 58.775% less volatile than S&P 500. In comparison Prenetics Global has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sino Biopharmaceutical has a quarterly dividend of $0.08 per share corresponding to a yield of 2.17%. Prenetics Global offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sino Biopharmaceutical pays -- of its earnings as a dividend. Prenetics Global pays out -- of its earnings as a dividend.

Sino Biopharmaceutical quarterly revenues are --, which are smaller than Prenetics Global quarterly revenues of $7.8M. Sino Biopharmaceutical's net income of -- is lower than Prenetics Global's net income of -$10.7M. Notably, Sino Biopharmaceutical's price-to-earnings ratio is 17.83x while Prenetics Global's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical is 2.16x versus 2.41x for Prenetics Global. Usually stocks with elevated PS ratios are considered overvalued.

Regencell Bioscience Holdings has a net margin of -- compared to Sino Biopharmaceutical's net margin of --. Sino Biopharmaceutical's return on equity of 8.57% beat Regencell Bioscience Holdings's return on equity of --.

Sino Biopharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Regencell Bioscience Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Sino Biopharmaceutical has higher upside potential than Regencell Bioscience Holdings, analysts believe Sino Biopharmaceutical is more attractive than Regencell Bioscience Holdings.

Sino Biopharmaceutical has a beta of 0.412, which suggesting that the stock is 58.775% less volatile than S&P 500. In comparison Regencell Bioscience Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sino Biopharmaceutical has a quarterly dividend of $0.08 per share corresponding to a yield of 2.17%. Regencell Bioscience Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sino Biopharmaceutical pays -- of its earnings as a dividend. Regencell Bioscience Holdings pays out -- of its earnings as a dividend.

Sino Biopharmaceutical quarterly revenues are --, which are smaller than Regencell Bioscience Holdings quarterly revenues of --. Sino Biopharmaceutical's net income of -- is lower than Regencell Bioscience Holdings's net income of --. Notably, Sino Biopharmaceutical's price-to-earnings ratio is 17.83x while Regencell Bioscience Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical is 2.16x versus -- for Regencell Bioscience Holdings. Usually stocks with elevated PS ratios are considered overvalued.